Evidence map›Paper›PMID 32630053›Full record

ReviewGenes2020

Utility of Common Marmoset (

Rajagopal N Aravalli, Clifford J Steer

Abstract readReview
In one paragraph

Review in Genes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rajagopal N AravalliDepartment of Electrical and Computer Engineering, College of Science and Engineering, University of Minnesota, 200 Union Street S.E., Minneapolis, MN 55455, USA.
Clifford J SteerDepartments of Medicine and Genetics, Cell Biology and Development, University of Minnesota, 420 Delaware Street S.E, Minneapolis MN 55455, USA.

Funding

NIH HHS DK117286-01
6 · The paper itself

Abstract

The incidence of liver disease is increasing significantly worldwide and, as a result, there is a pressing need to develop new technologies and applications for end-stage liver diseases. For many of them, orthotopic liver transplantation is the only viable therapeutic option. Stem cells that are capable of differentiating into all liver cell types and could closely mimic human liver disease are extremely valuable for disease modeling, tissue regeneration and repair, and for drug metabolism studies to develop novel therapeutic treatments. Despite the extensive research efforts, positive results from rodent models have not translated meaningfully into realistic preclinical models and therapies. The common marmoset

Indexed as

CallithrixDisease Models, AnimalAnimalsDrug DevelopmentEmbryonic Stem CellsLiver DiseasesStem Cell TransplantationTissue EngineeringbioengineeringCallithrix jacchuscell therapycytochrome P450drug metabolismembryonic stem cellhepatocyteliverliver diseasemarmosetregenerationtransplantation

Identifiers

PMID32630053
PMCPMC7397002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.